At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers want to find the best doses of abemaciclib and cabozantinib to use in people with advanced kidney cancer. The people in this study have clear cell renal cell carcinoma that metastasized (spread); they previously received other kidney cancer therapies. In addition, their cancer keeps growing even after 2 or 3 prior treatments, including checkpoint inhibitor immunotherapy.
-
The purpose of this study is to see how well avutometinib and defactinib work in people with thyroid cancer. The people in this study have one of these kinds of cancer:
-
Researchers want to see how well quizartinib works to treat acute myeloid leukemia (AML). The people in this study have AML that does not have a genetic change called FLT3-ITD. In addition, they have not yet had any treatment for AML.
- A Phase 1 Study of DAY301 in People With Advanced Solid Tumors
Full Title A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-drug Conjugate DAY301 in Patients with Locally Advanced or Metastatic Solid Tumors
Purpose
Researchers want to find the best dose of DAY301 to give to people with advanced solid tumors. The people in this study have solid tumors that have spread beyond their original location, including:
-
Head and neck cancer
-
Cancers of the esophagus, stomach, and gastroesophageal junction
- Non-small cell lung cancer and small cell lung cancer
- Gynecologic cancers: ovarian, endometrial, and cervical
-
Triple-negative breast cancer
DAY301 is a type of drug called an antibody-drug conjugate (ADC). ADCs are substances made up of a monoclonal antibody (special protein) linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and kills them. With ADCs, there is a lower risk of harming normal cells, since they usually do not have the target protein.
DAY301 targets cells with a protein called PTK7, which plays a role in cancer growth. By destroying these cells, DAY301 may help slow or stop the growth of your cancer. It is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have one of the advanced solid tumors listed above, which has spread beyond its original location.
- Have completed prior anti-cancer therapy at least 4 weeks before getting DAY301.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Robert Maki’s office at 646-888-5059.
Protocol
25-112Phase
Phase I (phase 1)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06752681ClinicalTrials.gov
-
-
The purpose of this study is to assess the safety and effectiveness of the investigational drug ZEN003694 in people with advanced squamous cell lung cancer that continues to grow despite treatment and contains multiple copies of a gene called NSD3. ZEN003694 blocks a group of proteins called BET, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of lung cancer. ZEN003694 is taken orally (by mouth).
- A Phase 1 Study of FT825 CAR T-Cell Therapy With or Without Cetuximab in People With Solid Tumors
Full Title A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors
Purpose
Researchers are assessing different doses of FT825 alone or with cetuximab to treat people with advanced solid tumors. Their tumors have high levels of the HER2 protein. Altered HER2 proteins can fuel cancer growth.
FT825 is a cellular therapy made from cells collected from a healthy donor. The donor cells are genetically modified (changed) to turn them into cells called induced pluripotent stem cells (iPSCs). iPSCs can be made to change into different cell types. In this study, iPSCs are used to make white blood cells called T cells. Some cancers can block T cells from attacking tumor cells.
Researchers will use genetically modified T cells to help them work against cancer cells. These modified T cells are called chimeric antigen receptor (CAR) T cells. Treatments made from them are called CAR T-cell therapies. They are a form of immunotherapy.
If you join this study, you will first get the chemotherapy drugs fludarabine and cyclophosphamide or bendamustine. These medicines help prepare your body for FT825. Some people whose cancer has an EGFR mutation will also receive cetuximab, a standard therapy for many cancers. The treatments are given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have an advanced solid tumor that makes high levels of HER2. Examples include breast, non-small cell lung, gastroesophageal junction, stomach, gynecologic, and colorectal cancers.
- Have completed prior anti-cancer treatments at least 2 weeks before getting the study therapy.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older
Contact
For more information or to see if you can join this study, please call Dr. Roisin O’Cearbhaill’s office at 646-608-2091.
Protocol
24-297Phase
Phase I (phase 1)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06241456ClinicalTrials.gov
-
Researchers are comparing several combination drug treatments for people with cancer of the stomach or gastroesophageal junction (GEJ). The people in this study have gastric or GEJ cancer that metastasized (spread) or is inoperable (cannot be surgically removed). In addition, their tumors make a protein called HER2.
-
Researchers want to find the best dose of RYZ801 to give with RYZ811 in people with inoperable liver cancer. Inoperable means the cancer cannot be taken out with surgery. The people in this study have hepatocellular carcinoma (HCC) that makes high levels of a liver protein called GPC3.
-
This study is comparing two treatment regimens for advanced pancreatic cancer. The people in this study have pancreatic ductal adenocarcinoma that has metastasized (spread). They have not yet had treatment for advanced disease.
-
Researchers are comparing different treatments for non-muscle invasive bladder cancer (NMIBC). The people in this study have NMIBC that keeps growing after treatment with an immunotherapy called Bacillus Calmette-Guerin (BCG). They do not want surgery to remove the bladder (radical cystectomy).